Menu
Search
|

Menu

Close
X

Protagonist Therapeutics Inc PTGX.OQ (NASDAQ Stock Exchange Global Market)

7.69 USD
-0.20 (-2.53%)
As of 11:45 AM EDT
chart
Previous Close 7.89
Open 7.89
Volume 4,555
3m Avg Volume 77,775
Today’s High 7.89
Today’s Low 7.66
52 Week High 23.68
52 Week Low 5.92
Shares Outstanding (mil) 21.20
Market Capitalization (mil) 167.93
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
11
FY17
20
FY16
0
FY15
0
EPS (USD)
FY18
-0.363
FY17
-2.165
FY16
-2.574
FY15
-1.019
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
5.44
8.11
Price to Book (MRQ)
vs sector
1.46
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
0.00
17.18
LT Debt to Equity (MRQ)
vs sector
0.00
13.08
Return on Investment (TTM)
vs sector
-32.09
13.18
Return on Equity (TTM)
vs sector
-32.21
15.09

EXECUTIVE LEADERSHIP

Harold Selick
Independent Chairman of the Board, Since
Salary: --
Bonus: --
Dinesh Patel
President, Chief Executive Officer, Director, Since 2008
Salary: $475,000.00
Bonus: --
Thomas O'Neil
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
David Liu
Chief Scientific Officer, Head of Research & Development, Since 2016
Salary: $357,000.00
Bonus: --
Richard Shames
Chief Medical Officer, Since 2015
Salary: $357,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7707 Gateway Blvd Ste 140
NEWARK   CA   94560-1160

Phone: +1510.4740170

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

SPONSORED STORIES